Cryotherapy + Tirbanibulin

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Keratosis

Conditions

Keratosis, Actinic Keratoses

Trial Timeline

Nov 30, 2025 → Nov 30, 2027

NCT ID

NCT07273656

About Cryotherapy + Tirbanibulin

Cryotherapy + Tirbanibulin is a phase 3 stage product being developed by Almirall for Keratosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07273656. Target conditions include Keratosis, Actinic Keratoses.

What happened to similar drugs?

5 of 20 similar drugs in Keratosis were approved

Approved (5) Terminated (0) Active (15)

✅Imiquimod + DiclofenacViatrisApproved

✅Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved

✅Tirbanibulin 2.5 mg ointmentAlmirallApproved

✅A-101 Topical SolutionAclaris TherapeuticsApproved

🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07273656	Phase 3	Recruiting	Nov 30, 2025	Nov 30, 2027	Keratosis

Competing Products

20 competing products in Keratosis

See all competitors

Product	Company	Stage	Hype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily	Dr. Reddy's Laboratories	Phase 2/3	35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel	Sun Pharmaceutical	Phase 1	29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical Cream	Sun Pharmaceutical	Phase 1	29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	29
Investigational Treatment + Active comparator	Novartis	Phase 2	35
KX01 ointment 1% + Placebo	PharmaEssentia	Phase 3	40
Imiquimod + Diclofenac	Viatris	Approved	40
Imiquimod 5 % Cream	Viatris	Phase 2	32
Aldara (Imiquimod)	Viatris	Phase 3	37
Imiquimod + Diclofenac	Viatris	Approved	40
Placebo Gel + LAS41005 + LAS106521	Almirall	Phase 3	34
5-fluorouracil/salicylic acid + Vehicle	Almirall	Phase 3	34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%	Almirall	Phase 2	29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel	Almirall	Approved	41
KX2-391 Ointment 1% + Placebo	Almirall	Phase 3	34
Tirbanibulin 2.5 mg ointment	Almirall	Approved	37
LAS41005	Almirall	Phase 2	29
Tirbanibulin	Almirall	Phase 3	34